Chemical biology is one of the most rapidly growing fields of investigation in the cancer field and beyond.

Chemical Biology Program

At Dana-Farber's Chemical Biology Program, we perform basic research in cancer chemical biology and develop new chemical probes and therapeutic strategies based on structural and mechanistic insights. We find inspiration in both unanswered biological
questions and unmet clinical needs.

The Chemical Biology Program is internationally recognized as a center of excellence in the field. Our chemical biology investigators have made important contributions to advancing targeted cancer therapy, and some of the compounds developed in the program
are now benefiting patients. What makes our program an exceptional place to do science are extraordinary and energetic graduate students, postdoctoral researchers, staff scientists, and technicians, who work relentlessly to provide chemistry-inspired
solutions targeting cancer, as well as infectious, neurodegenerative, and autoimmune diseases.

Our faculty members hold academic appointments at Dana-Farber's Department of Cancer Biology and Department of Pediatric Oncology,
as well as at Harvard Medical School. Our trainees come from a range of Harvard Medical School graduate programs, as well as Harvard's Graduate School of Arts and Sciences.

Our Research Focus

Our chemical biology efforts focus on developing new classes of small molecule modulators, like allosteric and covalent inhibitors and the degrader molecules, for challenging targets. We customize our chemical solutions to fit the biological and/or clinical questions being asked.

Protein-protein interactions (PPIs) mediate many of the cellular processes that are misfiring in cancer and other diseases. Yet, PPIs are notoriously difficult to target with small molecules. Our researchers are developing stapled peptides and other innovative strategies to better understand, control, and target PPIs.

Our structural biology and proteomics faculty solve structures of key molecular players that drive cancer and map their interactions. We use structural and proteomics information to frame and assist small molecule development and design, and as a window into selectivity, specificity, and the mechanism of action. Our program houses the Structural Biology Core and the Blais Proteomics Center.

Development of new pharmacologic agents requires extensive exploration of the chemical space to optimize the drug-like properties. Our medicinal chemistry faculty and the Medicinal Chemistry Core have expertise in transforming tool compounds into preclinical candidates.

Our faculty is developing new organic and analytical methodologies, as well as investigating basic principles of chemical and biological mechanisms, which serve as an essential fuel for our translational efforts.

At monthly faculty meetings, chemical biologists and their guests discuss ongoing research in their labs to foster collaboration and translation of chemical biology principles into basic and clinical advancements. The Degrader Club meets quarterly and focuses on rapid dissemination of knowledge on degrader technologies.

Medicinal chemist making new drugsSara Buhrlage, PhD, of Dana-Farber's Department of Cancer Biology and the Chemical Biology Program, explains the collaborative process of creating first-in-class drugs at Dana-Farber.

To learn more about the many ways you can support Dana-Farber's research initiatives with a philanthropic gift, please contact Rebecca Freedman at 617-632-4215 or rebecca_freedman@dfci.harvard.edu.

Contact Us

If you are interested in collaborating with our Chemical Biology Program investigators or in learning more about our research, please email our Program Director, Milka Kostic, PhD, or follow us on Twitter.